Shari Orlanski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shari Orlanski has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Amir Eden
Department of Genetics, Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Israel
2 shared publications - Aviad Zick
Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
2 shared publications - Benjamin P. Berman
Volition America LLC, Henderson, USA
2 shared publications - Efrat Katsman
Department of Developmental Biology and Cancer Research, Institute for Medical Research Israel-Canada, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
2 shared publications - Filippo Martignano
Core Research Laboratory, ISPRO, Florence, Italy
2 shared publications - Iacopo Petrini
Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy
2 shared publications
Latest Publications
- Open Access
- 15 July 2022
- Published by Springer Nature in Genome Biology
- Vol. 23 (1) , 1-25
Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for point-of-care real-time sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNAs) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy. Graphical Abstract
- 15 July 2022
- Published by Springer Nature in Genome Biology
- Vol. 23 (1) , 1-25
Open AccessDetecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for point-of-care real-time sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNAs) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy. Graphical Abstract
- Open Access
Detecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for clinical sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNA) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell-type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy, especially real-time medical applications.
Open AccessDetecting cell-of-origin and cancer-specific methylation features of cell-free DNA from Nanopore sequencing
The Oxford Nanopore (ONT) platform provides portable and rapid genome sequencing, and its ability to natively profile DNA methylation without complex sample processing is attractive for clinical sequencing. We recently demonstrated ONT shallow whole-genome sequencing to detect copy number alterations (CNA) from the circulating tumor DNA (ctDNA) of cancer patients. Here, we show that cell-type and cancer-specific methylation changes can also be detected, as well as cancer-associated fragmentation signatures. This feasibility study suggests that ONT shallow WGS could be a powerful tool for liquid biopsy, especially real-time medical applications.